Celaid Therapeutics
PrivateLast Round
Series B
Oct 7, 2025
Total Funding Raised
$34.78M
Company Overview
Celaid Therapeutics Inc. is a Japanese biotechnology startup from the University of Tokyo and University of Tsukuba, founded in 2020. The company has developed a proprietary platform for the large-scale, ex vivo expansion of human hematopoietic stem cells (HSCs). Its mission is to develop next-generation cell and gene therapy products to treat blood cancers, genetic disorders, and other intractable blood diseases. The technology allows for the expansion of HSCs from sources like bone marrow, cord blood, or peripheral blood without animal-derived components, enabling high-quality, low-cost production. Celaid is advancing its lead program, CLD-001, for pediatric non-malignant diseases and collaborates with partners to apply its technology to HSC gene therapies. The company has secured Series A funding and non-dilutive grants from the Japanese government.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Celaid Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Celaid Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 7, 2025 | ||||
| Series A Extension | Oct 31, 2024 | ||||
| Grant | Sep 30, 2024 | ||||
| Series A Extension | May 8, 2024 | ||||
| Grant | Mar 22, 2024 | ||||
Series A | Oct 25, 2022 |
Key People
Founding team and executive leadership
Celaid Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Japan Agency for Medical Research and Development | Series B |
| UTEC (The University of Tokyo Edge Capital Partners) | Series B, Series A Extension |
| Kobe University Innovation Fund | Series A Extension |
| Joyo Capital Partners | Series A Extension, Series B |
| SBI Regional Revitalization Support Corporation | Series A |
| Osaka University Venture Capital Co., Ltd. | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 20, 2025
Selected for the Shonan Health Innovation Conference in Boston.
- Oct 25, 2025
Attending the 2025 AABB/Cord Blood Connect event in San Diego.
Celaid Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Celaid Therapeutics's valuation, stock price, and market status.
